Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public offering of ordinary shares of Horizon Therapeutics Public Limited Company. Horizon’s ordinary shares are listed on the Nasdaq Global Select Market under the symbol “HZNP.”

Horizon is a specialty biopharmaceutical company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon’s global headquarters are in Dublin, Ireland.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Kimberly Wang and Joseph G. Marano. Partner Michael Farber and associate Shay Moyal provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associates Jay Frankel and Daniel P. Kearney. Members of the Davis Polk team are based in the Northern California and New York offices.